pharmaceuticals

pharmaceuticals Articles

The January 12 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
With the market trading at very extended valuations, and the S&P 500 on the longest streak ever without a 5% correction, it may make sense to move to some safer higher ground.
Eiger BioPharmaceuticals watched its shares crater on Tuesday after the firm announced that its midstage study in pulmonary arterial hypertension did not meet its primary endpoint.
Merck saw its shares make a handy gain on Tuesday after it reported that a late-stage trial of Keytruda met its dual primary endpoints.
The December 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Alder Biopharmaceuticals saw its shares make a solid gain on Monday amid a blizzard of updates from the company.
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
24/7 Wall St. screened the Stifel specialty pharmaceutical list and found five stock rated Buy that have massive upside potential and probably don’t have the investment risk of some of the more...
For the Jones Industrial Average to make its 2018 targets, Pfizer and Merck will to have to do their part to help. But they both lagged the markets in 2017.
Botox maker Allergan said Wednesday that it is firing 1,000 employees and eliminating about 400 unfilled job openings as it tries to make good on a promise to cut up to $400 million in costs in 2018.
Sangamo Therapeutics shares made a handy gain on hump day after the firm announced that it would be collaborating with pharma giant Pfizer.
Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should a study be...
Menlo Therapeutics, a late-stage biopharmaceutical company, has filed with the SEC regarding its initial public offering.
Progenics Pharmaceuticals saw its shares make a solid gain to close out the year after the FDA accepted for review the firm’s New Drug Application (NDA) for Azedra.
Jefferies has put together a list of 10 biotech companies that could have developments coming up in the next two weeks to start the year.